Inhibition of G protein-activated inwardly rectifying K+ channels by ifenprodil

Neuropsychopharmacology

Volumn 31, Issue 3, 2006, Pages 516-524

  Kobayashi, Toru ^a   Washiyama, Kazuo ^a   Ikeda, Kazutaka ^b  

^a NIIGATA UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

Ethanol; GIRK channel; Ifenprodil; Kir channel; Xenopus oocyte

Indexed keywords

ALCOHOL; G PROTEIN ACTIVATED INWARDLY RECTIFYING POTASSIUM CHANNEL 1; G PROTEIN ACTIVATED INWARDLY RECTIFYING POTASSIUM CHANNEL 2; G PROTEIN ACTIVATED INWARDLY RECTIFYING POTASSIUM CHANNEL 4; G PROTEIN COUPLED RECEPTOR; IFENPRODIL; KAPPA OPIATE RECEPTOR; MESSENGER RNA; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; PROTEIN SUBUNIT; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOASSAY; CELL PH; CHANNEL GATING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; EXTRACELLULAR SPACE; FEMALE; INHIBITION KINETICS; MEMBRANE BIOLOGY; MEMBRANE CHANNEL; NEUROPHARMACOLOGY; NONHUMAN; OOCYTE; PHARMACODYNAMICS; POTASSIUM CURRENT; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; SIGNAL TRANSDUCTION; XENOPUS;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; BRAIN CHEMISTRY; CENTRAL NERVOUS SYSTEM DEPRESSANTS; ETHANOL; FEMALE; G PROTEIN-COUPLED INWARDLY-RECTIFYING POTASSIUM CHANNELS; HUMANS; HYDROGEN-ION CONCENTRATION; MYOCARDIUM; OOCYTES; PIPERIDINES; PLASMIDS; POTASSIUM CHANNELS, INWARDLY RECTIFYING; RECEPTORS, G-PROTEIN-COUPLED; RNA, MESSENGER; XENOPUS;

EID: 33244472790     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300844     Document Type: Article

References (69)

1. 2+ channels and in gerbil global cerebral ischaemia. Eur J Pharmacol 299: 103-112.
2. KACh. J Biol Chem 277: 48282-48288.
3. Blednov YA, Stoffel M, Chang SR, Harris RA (2001). Potassium channels as targets for ethanol: studies of G-protein-coupled inwardly rectifying potassium channel 2 (GIRK2) null mutant mice. J Pharmacol Exp Ther 298: 521-530.
4. Brown AM, Birnbaumer L (1990). Ionic channels and their regulation by G protein subunits. Annu Rev Physiol 52: 197-213.
5. Carron C, Jullien A, Bucher B (1971). Synthesis and pharmacological properties of a series of 2-piperidino alkanol derivatives. Arzneim Forsch 21: 1992-1998.
6. 1 adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds. J Med Chem 34: 3085-3090.
7. Chizh BA, Headley PM, Tzschentke TM (2001). NMDA receptor antagonists as analgesics: focus on the NR2B subtype. Trends Pharmacol Sci 22: 636-642.
8. 2+ channels in rat and mouse cultured hippocampal pyramidal neurons: comparison with N-methyl-D-aspartate receptor antagonist actions. Br J Pharmacol 113: 499-507.
9. + channels. Cell Signal 9: 551-573.
10. + channel: expression cloning and molecular properties. Proc Natl Acad Sci USA 90: 10235-10239.
11. Doupnik CA, Davidson N, Lester HA (1995). The inward rectifier potassium channel family. Curr Opin Neurobiol 5: 268-277.
12. Fraser CM, Cooke MJ, Fisher A, Thompsom ID, Stone TW (1996). Interactions between ifenprodil and dizocilpine on mouse behaviour in models of anxiety and working memory. Eur Neurophermacol 6: 311-316.
13. Gawin FH, Kleber HD, Byck R, Rounsaville BJ, Kosten TR, Jatlow PI et al (1989). Desipramine facilitation of initial cocaine abstinence. Arch Gen Psychiatr 46: 117-121.
14. Gotti B, Duverger D, Bertin J, Carter C, Dupont R, Frost J et al (1988). Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. I. evidence for efficacy in models of focal cerebral ischemia. J Pharmacol Exp Ther 247: 1211-1221.
15. Gutstein HB, Akil H (2001). Opioid analgesics. In Hardman JG, Limbird LE, Gilman AG (eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10th edn. McGraw-Hill: New York, pp 569-619.
16. Hill KG, Alva H, Blednov YA, Cunningham CL (2003). Reduced ethanol-induced conditioned taste aversion and conditioned place preference in GIRK2 null mutant mice. Psychopharmacology 169: 108-114.
17. Ho K, Nichols CG, Lederer WJ, Lytton J, Vassilev PM, Kanazirska MV et al (1993). Cloning and expression of an inwardly rectifying ATP-regulated potassium channel. Nature 362: 31-38.
18. + (GIRK) channel. Mol Brain Res 45: 117-126.
19. + (GIRK) channels and functional couplings of the opioid receptors with the GIRK1 channel. Ann NY Acad Sci 801: 95-109.
20. + channel. Biochem Biophys Res Commun 208: 302-308.
21. Ikeda K, Kobayashi T, Kumanishi T, Yano R, Sora I, Niki H (2002). Molecular mechanisms of analgesia induced by opioids and ethanol: is the GIRK channel one of the keys? Neurosci Res 44: 121-131.
22. Ikeda K, Yoshii M, Sora I, Kobayashi T (2003). Opioid receptor coupling to GIRK channels. In vitro studies using a Xenopus oocyte expression system and in vivo studies on weaver mutant mice. Methods Mol Med 84: 53-64.
23. + channels composed of Kir3.2 subunits in dopaminergic neurons of the substantia nigra. J Neurosci 19: 1006-1017.
24. 3H](+)-3-PPP-labeled σ binding sites in guinea pig brain membranes. Eur J Pharmacol 193: 247-248.
25. + channel mRNAs are differentially expressed in the adult rat brain. J Neurosci 16: 3559-3570.
26. + channel (mGIRK1) and distinct distributions of three GIRK (GIRK1, 2 and 3) mRNAs in mouse brain. Biochem Biophys Res Commun 208: 1166-1173.
27. + channels. Nat Neurosci 2: 1091-1097.
28. + (GIRK) channel expressed in Xenopus oocytes. Br J Pharmacol 123: 421-426.
29. + (GIRK) channels expressed in Xenopus oocytes. Br J Pharmacol 129: 1716-1722.
30. Kobayashi T, Ikeda K, Kumanishi T (2002). Functional characterization of an endogenous Xenopus oocyte adenosine receptor. Br J Pharmacol 135: 313-322.
31. + channels by fluoxetine (Prozac). Br J Pharmacol 138: 1119-1128.
32. + channels: potentially therapeutic agents for addictive drug users. Ann NY Acad Sci 1025: 590-594.
33. + channels by various antidepressant drugs. Neuropsychopharmacology 29: 1841-1851.
34. Kobayashi T, Washiyama K, Ikeda K (2004c). Effects of interferon-α on cloned opioid receptors expressed in Xenopus oocytes. Life Sci 76: 407-415.
35. +-channel proteins. Nature 374: 135-141.
36. Kubo Y, Baldwin TJ, Jan YN, Jan LY (1993a). Primary structure and functional expression of a mouse inward rectifier potassium channel. Nature 362: 127-133.
37. Kubo Y, Reuveny E, Slesinger PA, Jan YN, Jan LY (1993b). Primary structure and functional expression of a rat G-protein-coupled muscarinic potassium channel. Nature 364: 802-806.
38. Kuzhikandathil EV, Oxford GS (2002). Classic D1 dopamine receptor antagonist R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3- benzazepine hydrochloride (SCH23390) directly inhibits G protein-coupled inwardly rectifying potassium channels. Mol Pharmacol 62: 119-126.
39. + channels. J Biol Chem 270: 28660-28667.
40. Lewohl JM, Wilson WR, Mayfield RD, Brozowski SJ, Morrisett RA, Harris RA (1999). G-protein-coupled inwardly rectifying potassium channels are targets of alcohol action. Nat Neurosci 2: 1084-1090.
41. + channel proteins GIRK1 and GIRK2 and their altered expression in weaver brain. J Neurosci 16: 7137-7150.
42. + channels (GIRKs) mediate postsynaptic but not presynaptic transmitter actions in hippocampal neurons. Neuron 19: 687-695.
43. Malinowska B, Napiórkowska-Pawlak D, Pawlak R, Buczko W, Göthert M (1999). Ifenprodil influences changes in mouse behaviour related to acute and chronic ethanol administration. Eur J Pharmacol 377: 13-19.
44. Marquis P, Lecasble M, Passa P (1998). Quality of life of patient with peripheral arterial obliterative disease treated with ifenprodil tartate. Results of an ARTEMIS study. Drugs 56(Suppl 3): 37-48.
45. McCool BA, Lovinger DM (1995). Ifenprodil inhibition of 5-hydroxytryptamine3 receptor. Neuropharmacol 34: 621-629.
46. Mikolajczak P, Okulicz-Kozaryn I, Kaminska E, Szulc M, Dyr W, Kostowski W (2003). Lack of ifenprodil anxiolytic activity after its multiple treatment in chronically ethanol-treated rats. Alcohol Alcholism 38: 310-315.
47. Mizusawa H, Yamane M, Sakai K (1976). Effects of ifenprodil tartate on the autonomic, peripheral and central nervous system. Folia Pharmacol Jpn 72: 185-199.
48. Morgan AD, Carroll ME, Loth AK, Stoffel M, Wickman K (2003). Decreased cocaine self-administration in Kir3 potassium channel subunit knockout mice. Neuropsychopharmacology 28: 932-938.
49. Nakagawa H, Yamano S, Nikawa K, Matsumoto Y, Suga T (1975). Metabolic fate of dl-erythro-2-(4-benzylpiperidino)-1-(4-hydrophenyl)-1-propanol I. Absorption, distribution and excretion in the rat and mouse. Pharmacometrics 10: 283-291.
50. Napiórkowska-Pawlak D, Malinowska B, Pawlak R, Buczko W, Göthert M (2000). Attenuation of the acute amnesic effect of ethanol by ifenprodil: comparison with ondansetron and dizocilpine. Fundam Clin Pharmacol 14: 125-131.
51. Narita M, Soma M, Narita M, Mizoguchi H, Tseng LF, Suziki T (2000). Implications of the NR2B subunit-containing NMDA receptor localized in mouse limbic forebrain in ethanol dependence. Eur J Pharmacol 401: 191-195.
52. Nash JE, Fox SH, Henry B, Hill MP, Peggs D, McGuire S et al (2000). Antiparkinsonian actions of ifenprodil in MPTP-lesioned marmoset model of Parkinson's disease. Exp Neurol 165: 136-142.
53. North RA (1989). Drug receptors and the inhibition of nerve cells. Br J Pharmacol 98: 13-28.
54. Otomo E, Kodama R, Tazaki Y, Nukada T, Fujishima M (1976). Double blind study of FX-505 (ifenprodil) on cerebrovascular disease -Phase III study- FX-505 project for phase III study. Clin Eval 4: 419-458.
55. Reimann F, Ashcroft FM (1999). Inwardly rectifying potassium channels. Curr Opin Cell Biol 11: 503-508.
56. Reuveny E, Slesinger PA, Inglese J, Morales JM, Iniguez-Lluhi JA, Lefkowitz RJ et al (1994). Activation of the cloned muscarinic potassium channel by G protein βγ subunits. Nature 370: 143-146.
57. + channel GIRK2. Proc Natl Acad Sci USA 94: 923-927.
58. + channels: Kir2.0 and Kir3.0. Rev Physiol Biochem Pharmacol 145: 47-179.
59. Suzuki T, Kato H, Tsuda M, Suzuki H, Misawa M (1999). Effects of the non-competitive NMDA receptor antagonist ifenprodil on the morphine-induced place preference in mice. Life Sci 64: PL151-156.
60. 2+-free model of epileptiform activity in rat hippocampal slices. Br J Pharmacol 124: 917-929.
61. Torrecilla M, Marker CL, Cintora SC, Stoffel M, Williams JT, Wickman K (2002). G-protein-gated inwardly rectifying potassium channels containing Kir3.2 and Kir3.3 subunits mediate the acute inhibitory effects of opioids on locus ceruleus neurons. J Neurosci 22: 4328-4334.
62. Wickman K, Nemec J, Gendler SJ, Clapham DE (1998). Abnormal heart rate regulation in GIRK4 knockout mice. Neuron 20: 103-114.
63. Wickman K, Seldin MF, Gendler SJ, Clapham DE (1997). Partial structure, chromosome localization, and expression of the mouse Girk4 gene. Genomics 40: 395-401.
64. Williams K (2001). Ifenprodil, a novel NMDA receptor antagonist: site and mechanism of action. Curr Drug Targets 2: 285-298.
65. Witkin JM, Acri JB (1995). Effects of ifenprodil on stimulatory, discriminative stimulus, and convulsant effects of cocaine. Behav Pharmacol 6: 245-253.
66. Yajima T, Urano T, Nakamura K, Matsuura A, Nakamura K (1987). Cerebral vasodilating and vasospasmolytic action of the cerebral circulation improver 6,7-dimethoxy-1-(3,4-dimethoxybenzyl)-4-([4-(2-methoxyphenyl)-1-piperazinyl] methyl)isoquininoline in experimental animals. Arzneim Forsch 37: 379-383.
67. Young AR, Barry DI, MacKenzie ET, Robert J-P (1983). Cerebrocirculatory effects of so-called 'vasodilators' in the anaesthetised rat. Eur Neurol 22: 142-153.
68. Yourick DL, Repasi RT, Rittase WB, Stanten LD, Meyerhoff JL (1999). Ifenprodil and arcaine alter amygdala-kinding development. Eur J Pharmacol 371: 147-152.
69. + channels. Proc Natl Acad Sci USA 98: 6482-6287.